Article

DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCs

2024-11-06

Abstract excerpt

<h4>Background</h4> Metabolic dysfunction-associated steatotic liver disease (MAFLD) has a high prevalence and high co-morbidity for other diseases. Due to the complexity of this multifactorial disease, therapy options are still rather limited. We employed an in vitro pluripotent stem cell-based model to decipher potential disease-associated molecular pathways and to study the mode of action of prospective drugs...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c4b23b4a-1a37-5853-b69f-1143015a7bb2
DOI: 10.1101/2024.11.06.622222

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCsDOI 10.1101/2024.11.06.622222Read

Inhibiting DPP4 activity protects hiPSC-derived steatotic HLCs by supporting fatty acid and purine metabolism and dampening inflammationSemantic proximity Read

Predicting Metabolic Dysfunction Associated Steatotic Liver Disease Risk Using Patient-Derived Induced Pluripotent Stem CellsSemantic proximity Read

Characterization Of Human Pluripotent Stem Cell-Derived Hepatocytes With Adult Features And Potential For Modeling Metabolic DiseasesSemantic proximity Read

Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver DiseaseSemantic proximity Read

<i>Patolakaturohiniyadi Kashayam</i> , exerts anti-steatotic and anti-obesogenic effects via coordinated regulation of lipid metabolism, inflammation, and incretin signallingSemantic proximity Read

MASLD-Induced Liver Micro-Organoids Mimics Clinical Observations of Impaired Vitamin D SynthesisSemantic proximity Read

Explore of potential targets and mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experimentsSemantic proximity Read

MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticlesSemantic proximity Read

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity Read

Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision TherapySemantic proximity Read

Pigment epithelium-derived factor (PEDF) suppresses IL-1β-mediated c-Jun N-terminal kinase (JNK) activation to improve hepatocyte insulin signaling.Semantic proximity Read

A long-acting FGF21 attenuates metabolic dysfunction-associated steatohepatitis-related fibrosis by modulating NR4A1-mediated Ly6C phenotypic switch in macrophages.Semantic proximity Read